Skip to main content
. Author manuscript; available in PMC: 2016 Jun 23.
Published in final edited form as: Clin Cancer Res. 2007 Dec 15;13(24):7401–7406. doi: 10.1158/1078-0432.CCR-07-0781

Table 5.

Relative pharmacokinetic comparisons of i.v. temsirolimus

Study Temsirolimus
 Sirolimus
Dose
(mg)		 Cmax
(μg/mL)		 AUC
(μg × h/mL)		 CL
(L/h)		 Vdss
(L)		 Cmax
(ng/mL)		 AUC
(μg × h/mL)		 AUCsum
(μg × h/mL)		 168 h trough
(ng/mL)
Non-EIAEDs
 Atkins et al. (15) 250
(n = 6)		 2.83
(±0.87)		 2.70
(±0.72)		 98
(±26)		 897
(±316)		 266
(±93)		 13.30
(±3.70)		 16.00
(±3.59)		 –
 Current study 250
(n = 6)		 2.36
(±0.16)		 5.03
(±2.92)		 66
(±42)		 470
(±362)		 261
(±125)		 14.49
(±4.94)		 19.52
(±6.65)		 14.97 (±6.30),
n =4
EIAEDs
 Galanis et al. (7) 250
(n = 6)		 1.07
(±0.68)		 3.39
(±1.34)		 83
(±31)		 978
(±292)		 134
(±26)		 5.89
(±1.80)		 9.28
(±0.40)		 2.80 (±1.66)
 Current study 250
(n = 13)		 1.45
(±0.89)		 3.32
(±0.84)		 80
(±18)		 699
(±241)		 132
(±46)		 6.83
(±3.28)		 9.74
(±3.67)		 6.82 (±0.38),
n = 4